Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial

详细信息    查看全文

• 作者：Anai E. S. Durazzo ; Fá ; bio S. Machado ; Dimas T. Ikeoka ; Clá ; udia De Bernoche ; Maristela C. Monachini ; Pedro Puech-Leã ; o ; Bruno Caramelli
• 关键词：Thoracic aorta aneurysm ; aortotracheal fistula ; aortoesophageal fistula
• 刊名：Journal of Vascular Surgery
• 出版年：2004
• 出版时间：May 2004
• 年：2004
• 卷：39
• 期：5
• 页码：967-975
• 全文大小：151 K

文摘

This prospective, randomized, placebo-controlled, double-blind clinical trial was performed to analyze the effect of atorvastatin compared with placebo on the occurrence of a 6-month composite of cardiovascular events after vascular surgery. Cardiovascular complications are the most important cause of perioperative morbidity and mortality among patients undergoing vascular surgery. Statin therapy may reduce perioperative cardiac events through stabilization of coronary plaques.toc2"">

Methods

One hundred patients were randomly assigned to receive 20 mg atorvastatin or placebo once a day for 45 days, irrespective of their serum cholesterol concentration. Vascular surgery was performed on average 30 days after randomization, and patients were prospectively followed up over 6 months. The cardiovascular events studied were death from cardiac cause, nonfatal myocardial infarction, unstable angina, and stroke.toc3"">

Results

Fifty patients received atorvastatin, and 50 received placebo. During the 6-month follow-up primary end points occurred in 17 patients, 4 in the atorvastatin group and 13 in the placebo group. The incidence of cardiac events was more than three times higher with placebo (26.0 % ) compared with atorvastatin (8.0 % ; P = .031). The risk for an event was compared between the groups with the Kaplan-Meier method, as event-free survival after vascular surgery. Patients given atorvastatin exhibited a significant decrease in the rate of cardiac events, compared with the placebo group, within 6 months after vascular surgery (P = .018).toc4"">

Conclusion

Short-term treatment with atorvastatin significantly reduces the incidence of major adverse cardiovascular events after vascular surgery.